What question did this study set out to answer?

To evaluate the efficacy and safety of extended adjuvant therapy with the aromatase inhibitor letrozole compared to placebo in postmenopausal women with early-stage breast cancer who have completed approximately five years of adjuvant tamoxifen therapy.

February 23, 2004Obstetrical & Gynecological Survey

A Randomized Trial of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy and safety of extended adjuvant therapy with the aromatase inhibitor letrozole compared to placebo in postmenopausal women with early-stage breast cancer who have completed approximately five years of adjuvant tamoxifen therapy.
Randomized, double-blind, placebo-controlled clinical trial.
Postmenopausal women with hormone receptor-positive early-stage breast cancer who completed 4.5 to 6 years of adjuvant tamoxifen were assigned to receive letrozole or placebo.
Letrozole therapy significantly improves disease-free survival compared to placebo in postmenopausal women completing standard tamoxifen treatment.
Treatment with letrozole substantially reduces the risk of distant recurrence and contralateral breast cancer.

Implication

Randomized trial demonstrates improved outcomes with letrozole in postmenopausal breast cancer after tamoxifen, indicating benefits of extended endocrine therapy.

Abstract

Goss, Paul E.; Ingle, James N.; Martino, Silvana; Robert, Nicholas J.; Muss, Hyman B.; Piccart, Martine J.; Castiglione, Monica; Tu, Dongsheng; Shepherd, Lois E.; Pritchard, Kathleen I.; Livingston, Robert B.; Davidson, Nancy E.; Norton, Larry; Perez, Edith A.; Abrams, Jeffrey S.; Therasse, Patrick; Palmer, Michael J.; Pater, Joseph L.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Goss et al. (2004) studied this question.

synapsesocial.com/papers/6a1269afa4bed3c7b16710c8 https://doi.org/10.1097/01.ogx.0000115858.45890.53

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates improved outcomes with letrozole in postmenopausal breast cancer after tamoxifen, indicating benefits of extended endocrine therapy.

A Randomized Trial of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

A Randomized Trial of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading